EMEA-001748-PIP03-19
Table of contents
Key facts
| Active substance |
arimoclomol citrate
|
| Therapeutic area |
Neurology
|
| Decision number |
P/0012/2021
|
| PIP number |
EMEA-001748-PIP03-19
|
| Pharmaceutical form(s) |
Capsule, hard
|
| Condition(s) / indication(s) |
Treatment of amyotrophic lateral sclerosis
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Orphazyme A/S
Email: contact@orphazyme.com |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|